Guggenheim resumed coverage on ORIC Pharmaceuticals with a new price target
$ORIC
Biotechnology: Pharmaceutical Preparations
Health Care
Guggenheim resumed coverage of ORIC Pharmaceuticals with a rating of Buy and set a new price target of $18.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/4/2025 | $18.00 | Buy | Guggenheim |
| 7/8/2025 | $15.00 | Buy | Ladenburg Thalmann |
| 10/31/2024 | $20.00 | Overweight | Wells Fargo |
| 9/6/2024 | $20.00 | Buy | Stifel |
| 2/23/2024 | Overweight | Cantor Fitzgerald | |
| 9/22/2023 | $8.00 | Outperform | Wedbush |
| 3/23/2023 | $16.00 | Neutral → Buy | H.C. Wainwright |
| 3/21/2023 | $15.00 | Neutral → Buy | Guggenheim |
Guggenheim resumed coverage of ORIC Pharmaceuticals with a rating of Buy and set a new price target of $18.00
Ladenburg Thalmann initiated coverage of ORIC Pharmaceuticals with a rating of Buy and set a new price target of $15.00
Wells Fargo initiated coverage of ORIC Pharmaceuticals with a rating of Overweight and set a new price target of $20.00
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on September 2, 2025 (the "Grant Date"), ORIC granted a total of 292,500 non-qualified stock options and 79,000 restricted stock units to one new non-executive officer employee who began their employment with ORIC in August 2025. These inducement grants were granted pursuant to the ORIC Pharmaceuticals, Inc. 2022 Inducement Equity Incentive Plan, subject to recipient's continued employment or service through each applicable vesting da
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Aug. 27, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will be participating in the following investor conferences in September: Citi's 2025 Biopharma Back to School Summit – Participating in a fireside chat on Wednesday, September 3, 2025, at 4:00 p.m. ET. Management will also be participating in one-on-one meetings.2025 Wells Fargo Healthcare Conference – Participating in a fireside chat on Thursday, September 4, 2025, at 2:15 p.m. ET. Management will also be participating i
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Aug. 18, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced the appointment of Kevin Brodbeck, PhD, to the newly established role of Chief Technical Officer (CTO). Dr. Brodbeck brings more than 25 years of experience leading technical operations, quality assurance, chemistry, manufacturing and controls (CMC), and regulatory activities across a wide range of pharmaceutical products at all stages of development and commercialization. The creation of the CTO role and Dr. Brodbeck's appointment reflect t
SCHEDULE 13G/A - Oric Pharmaceuticals, Inc. (0001796280) (Subject)
10-Q - Oric Pharmaceuticals, Inc. (0001796280) (Filer)
8-K - Oric Pharmaceuticals, Inc. (0001796280) (Filer)
4 - Oric Pharmaceuticals, Inc. (0001796280) (Issuer)
4 - Oric Pharmaceuticals, Inc. (0001796280) (Issuer)
4 - Oric Pharmaceuticals, Inc. (0001796280) (Issuer)
4 - Oric Pharmaceuticals, Inc. (0001796280) (Issuer)
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Aug. 18, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced the appointment of Kevin Brodbeck, PhD, to the newly established role of Chief Technical Officer (CTO). Dr. Brodbeck brings more than 25 years of experience leading technical operations, quality assurance, chemistry, manufacturing and controls (CMC), and regulatory activities across a wide range of pharmaceutical products at all stages of development and commercialization. The creation of the CTO role and Dr. Brodbeck's appointment reflect t
Reported encouraging early safety and efficacy data in ongoing dose escalation trial for ORIC-944 in combination with androgen receptor inhibitors in patients with mCRPC Entered into clinical trial collaboration and supply agreement with Johnson & Johnson to evaluate ORIC-114 in combination with subcutaneous amivantamab for the first-line treatment of NSCLC patients with EGFR exon 20 insertion mutations Expects to report seven data readouts across ORIC-114 and ORIC-944 clinical programs over the next 18 months, with potential initiation of registrational trials in 2H25 and early 2026 Cash and investments of $256 million expected
Announces encouraging early safety and efficacy data in ongoing dose escalation trial for ORIC-944 in combination with apalutamide in patients with mCRPC Entered into clinical trial collaboration and supply agreement with Johnson & Johnson to evaluate ORIC-114 in combination with subcutaneous amivantamab for the first-line treatment of NSCLC patients with EGFR exon 20 insertion mutations Expects to report seven data readouts across ORIC-114 and ORIC-944 clinical programs over the next 18 months, with potential initiation of registrational trials in 2H25 and early 2026 Cash and investments expected to fund operating plan into late 2026 SOUTH SAN FRANCISCO and SAN DIEGO, J
SC 13G/A - Oric Pharmaceuticals, Inc. (0001796280) (Subject)
SC 13G/A - Oric Pharmaceuticals, Inc. (0001796280) (Subject)
SC 13G/A - Oric Pharmaceuticals, Inc. (0001796280) (Subject)
Broad and deep PSA responses achieved, with 59% PSA50 response rate (confirmed rate of 47%, and one additional response pending confirmation) and 24% PSA90 response rate (all confirmed) in patients with mCRPC PSA responses were observed across all ORIC-944 dose levels and at comparable rates in combination with apalutamide and with darolutamide; majority of patients are still ongoing with multiple patients approaching one year or more Both combination regimens demonstrated a safety profile compatible with long term dosing, with the vast majority of adverse events Grade 1 or 2 Announced concurrent $125 million financing, which extends cash runway into 2H 2027 and through anticipated
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, May 27, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that the company will present initial data from the Phase 1b trial of ORIC-944 in combination with androgen receptor inhibitors in patients with metastatic castration resistant prostate cancer (mCRPC) in a conference call and webcast on Wednesday, May 28, 2025, at 4:30 p.m. ET. To join the conference call via phone and participate in the live Q&A session, please pre-register online here to receive a telephone number and unique passcode req
Preliminary evidence of clinical antimyeloma activity, including reduction in paraprotein, demonstrated in multiple patients Clean safety profile with only Grade 1 and 2 treatment related adverse events and no dose limiting toxicities or dose reductions Clinical activity, safety profile, and dose-dependent increases in immune cell activation support potential for combination studies with other multiple myeloma agents, including BCMA- and CD38-directed therapies Company to pursue strategic partnership for combination studies, resulting in extension of cash runway into 2026 Company to host conference call and webcast today at 4:30 pm ET SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Dec. 11